Fig. 3From: Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphomaProgression-free survival (PFS, a) and overall survival (OS, b) of patients treated with and without consolidation high dose chemotherapy and ABSCT in dependency of rituximab treatment (with rituximab N = 7 and N = 38; without rituximab N = 17 and N = 18). Due to multiple testing (k = 4) a P-value <0.013 is considered as statistically significantBack to article page